Defence Therapeutics Inc (CSE:DTC)

0.3900 -0.0100 (-2.50%)

Delayed Quote Updated: 2:48 PM EDT, Oct 2, 2026 Add to My Watchlist

Price and Volume

Volume	43,500
Open	0.3750
Bid (Size)	0.3750 (1,000)
Ask (Size)	0.4350 (2,500)
Prev. Close	0.4000
Today's Range	0.3700 - 0.4000
52wk Range	0.3650 - 0.9300
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Life Sciences Virtual Investor Forum Agenda Announced for December 11th

December 09, 2025

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Precision Medicine Helps Conquer Advanced-Stage Cancer

November 14, 2023

As North America reports a dramatic rise in advanced-stage cancer cases, experts are saying that major breakthroughs in oncology could make “now the best time in human history to get cancer.” According...

Via PressReach

Performance

52-Week Range 58.1% below 52-week high

0.3900

0.3652W Low 0.9352W High

1 Week 12.4% below 1-week high

0.371W Low 0.451W High

Defence Therapeutics Inc (DTC) traded between $0.36 and $0.93 over the past 52 weeks and last traded at $0.39, 58.1% below its 52-week high. Over the past week it ranged between $0.37 and $0.45.

Past 12 Months

-2.5%

-22.0%

-10.3%

-30.4%

-44.3%

-48.0%

1W -$0.01

1M -$0.11

3M -$0.04

6M -$0.17

YTD -$0.31

1Y -$0.36

DTC was -48.0% over the past year, -30.4% over six months, -44.3% year to date, -2.5% in the last week.

12 Months vs Market

DTC

-48.0%

DIA

+9.9%

SPY

+15.0%

QQQ

+23.7%

IWM

+15.4%

Over the past 12 months DTC returned -48.0% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 1.04× 3-mo avg

Today 43,500 3-mo avg 42.0K

70.5K

35.3K

42.0K

45.3K

YTD

44.2K

50.6K

DTC most recently traded 43,500 shares against a 3-month average daily volume of 42.0K.

More News

Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors

November 14, 2023

Via PressReach

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

November 14, 2023

Via FinancialNewsMedia

Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology

November 07, 2023

Via PressReach

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

Via FinancialNewsMedia

Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer

October 18, 2023

Via PressReach

Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race

October 17, 2023

Via PressReach

Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology

October 17, 2023

Via PressReach

Defence’s Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma

October 17, 2023

Via PressReach

Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race

October 10, 2023

Via PressReach

Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies

October 10, 2023

Via PressReach

Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science

October 10, 2023

Via PressReach

Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines

September 26, 2023

Via PressReach

BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment

May 10, 2023

Via Newsfile

BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News

May 04, 2023

Via Newsfile

BTV Features: Defence Therapeutics, Volatus Aerospace, NGEx Minerals, York Harbour Metals, & AuTECO Minerals

November 10, 2022

Via Newsfile

Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market

September 29, 2022

Via Newsfile

Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma

September 21, 2022

Via Newsfile

Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative

September 16, 2022

Via Newsfile

The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants

July 06, 2021

Via Newsfile

Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer

June 29, 2021

Via Newsfile

Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties

June 22, 2021

Via Newsfile

Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic

June 07, 2021

Via Newsfile

RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program

June 01, 2021

Via Newsfile

Frequently Asked Questions

Is Defence Therapeutics Inc publicly traded?

Yes, Defence Therapeutics Inc is publicly traded.

What exchange does Defence Therapeutics Inc trade on?

Defence Therapeutics Inc trades on the Canadian Securities Exchange

What is the ticker symbol for Defence Therapeutics Inc?

The ticker symbol for Defence Therapeutics Inc is DTC on the Canadian Securities Exchange

What is the current price of Defence Therapeutics Inc?

The current price of Defence Therapeutics Inc is 0.3900

When was Defence Therapeutics Inc last traded?

The last trade of Defence Therapeutics Inc was at 10/02/26 02:48 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.